Skip to main content
logo
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.47
+0.91 (4.03%)
At close: Feb 6, 2026, 4:00 PM EST
23.49
+0.02 (0.09%)
After-hours: Feb 6, 2026, 4:10 PM EST

Apellis Pharmaceuticals Revenue

Apellis Pharmaceuticals had revenue of $458.58M in the quarter ending September 30, 2025, with 132.98% growth. This brings the company's revenue in the last twelve months to $1.02B, up 42.11% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.

Revenue (ttm)
$1.02B
Revenue Growth
+42.11%
P/S Ratio
2.90
Revenue / Employee
$1,431,545
Employees
710
Market Cap
2.97B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024781.37M384.78M97.02%
Dec 31, 2023396.59M321.17M425.83%
Dec 31, 202275.42M8.86M13.31%
Dec 31, 202166.56M-184.08M-73.44%
Dec 31, 2020250.65M--
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Legend Biotech909.05M
Catalyst Pharmaceuticals578.20M
IDEAYA Biosciences214.83M
Viridian Therapeutics70.79M
Immunome9.68M
Xenon Pharmaceuticals7.50M
Revenue Rankings

APLS News

More News